U.S. Commercial Services Stock News

NYSE:ARI
NYSE:ARIMortgage REITs

A Look At Apollo Commercial Real Estate Finance (ARI) Valuation As Returns Fuel Mixed Signals On Pricing

Recent performance snapshot Apollo Commercial Real Estate Finance (ARI) has drawn investor attention after a recent 1 day return of 0.91%, capping a month return of 3.86% and past 3 months return of 2.41%. Over longer periods, the mortgage REIT shows a year to date total return of 11.97%, with 1 year, 3 year and 5 year total returns of 28.59%, 63.59% and 28.996% respectively, against a recent close of US$11.04. See our latest analysis for Apollo Commercial Real Estate Finance. The recent...
NYSE:HAE
NYSE:HAEMedical Equipment

Is It Time To Reassess Haemonetics (HAE) After Recent Share Price Swings?

If you are wondering whether Haemonetics at around US$59.26 is a bargain or just fairly priced right now, this article walks through what the numbers say about its value. The stock has seen mixed returns, with a 1.1% decline over the last 7 days, a 4.3% gain over 30 days, and year to date and 1 year returns of 25.9% and 7.2% declines. These movements may be prompting new questions about risk and opportunity. Recent news coverage has focused on Haemonetics as part of broader discussions...
NasdaqGS:IRDM
NasdaqGS:IRDMTelecom

Did Flat Service-Revenue Guidance and Softer EPS Just Shift Iridium Communications' (IRDM) Investment Narrative?

In the first quarter of 2026, Iridium Communications Inc. reported revenue of US$219.06 million versus US$214.88 million a year earlier, while net income fell to US$21.59 million from US$30.41 million and diluted EPS from continuing operations eased to US$0.20 from US$0.27. Iridium also reiterated its 2026 outlook for total service revenue to be flat to 2%, signaling a cautious near-term growth profile despite higher quarterly sales. With Iridium reaffirming expectations for flat to slightly...
NasdaqGS:LSTR
NasdaqGS:LSTRTransportation

A Look At Landstar System (LSTR) Valuation After Q1 Results And Heavy Haul And AI Initiatives

What Landstar’s latest quarter tells you Landstar System (LSTR) just released first quarter results, with sales of US$1,149.56 million and net income of US$39.44 million, and reported basic EPS from continuing operations of US$1.16. Management also highlighted heavy haul revenue, lower insurance and claims costs, AI-related initiatives, and a focus on U.S. Mexico cross border freight and carrier vetting, giving investors more context than the headline numbers alone. See our latest analysis...
NYSE:DCI
NYSE:DCIMachinery

A Look At Donaldson Company (DCI) Valuation After Mixed Share Price Performance

Donaldson Company stock overview Donaldson Company (DCI) has drawn investor attention after a mixed stretch for the share price, with a negative move over the past 3 months contrasting with a positive total return over the past year. At a recent close of $86.22, the filtration specialist and its segments across Mobile Solutions, Industrial Solutions, and Life Sciences are set against a backdrop of single digit annual revenue growth and double digit annual net income growth. See our latest...
NYSE:CARR
NYSE:CARRBuilding

Carrier Global (CARR) Valuation Check After Q1 Beat And Surging Data Center Orders

Carrier Global (CARR) is back in focus after Q1 2026 results topped expectations, total orders rose 11%, and data center demand was strong enough to fully cover the company’s targeted 2026 sales. See our latest analysis for Carrier Global. The Q1 beat and reaffirmed 2026 guidance have been met with strong buying interest, with a 21.38% 1 month share price return and 26.35% year to date, even though the 1 year total shareholder return is down 4.42%, so momentum is clearly building off a longer...
NYSE:FUL
NYSE:FULChemicals

Assessing H.B. Fuller (FUL) Valuation As Shares Trade Below Narrative Fair Value

How H.B. Fuller Stock Has Been Trading Recently H.B. Fuller (FUL) has seen relatively muted share performance lately, with the stock around $59.95 and negative returns over the past week, month, and past 3 months, despite a positive 1 year total return. For context, the company carries a market value of about $3.27b and generates annual revenue of roughly $3.46b with net income of about $159.76m. This reflects its role as an established adhesives and specialty chemicals supplier. See our...
NYSE:DVA
NYSE:DVAHealthcare

Is It Time To Reassess DaVita (DVA) After Its Strong Year To Date Rally

If you are wondering whether DaVita at around US$151.65 is still priced reasonably or already baking in a lot of optimism, the next sections will help you frame that question clearly. The stock's recent performance has been mixed in the short term, with a 0.1% decline over 7 days, a 4.2% gain over 30 days, and longer term returns of 32.4% year to date, 7.5% over 1 year, 71.4% over 3 years, and 19.6% over 5 years. Recent coverage has focused on DaVita's role in the US healthcare system and...
NasdaqGM:KOD
NasdaqGM:KODBiotechs

Assessing Kodiak Sciences (KOD) Valuation After New KSI-101 Retinal Trial Updates

Kodiak Sciences (KOD) is back in focus after sharing new KSI-101 clinical data in Asian MESI patients at the AUS and ARVO meetings, reinforcing interest in its expanding retinal disease pipeline. See our latest analysis for Kodiak Sciences. The clinical updates around KSI-101 arrive after a sharp re-rating in Kodiak Sciences, with the share price at US$43.96 and a 90-day share price return of 82.33%, contributing to a very large 1-year total shareholder return, while the 5-year total...
NasdaqGS:PEGA
NasdaqGS:PEGASoftware

A Look At Pegasystems (PEGA) Valuation After Blueprint AI Momentum And Mixed Q1 Results

Pegasystems (PEGA) is back in focus after first quarter earnings showed revenue of US$429.97 million and net income of US$32.76 million, alongside growing attention on its AI native Blueprint platform and customer engagement trends. See our latest analysis for Pegasystems. The first quarter update and growing attention on the Blueprint platform come against a tougher trading backdrop, with a 30 day share price return showing a 15.06% decline and year to date share price return showing a...
NYSE:HUBS
NYSE:HUBSSoftware

A Look At HubSpot (HUBS) Valuation As AI Momentum And SaaS Sector Optimism Lift Sentiment

HubSpot (HUBS) has been back in focus after a sector wide lift in software as a service names, as well as growing attention on its AI products, customer growth, and upcoming earnings report. See our latest analysis for HubSpot. The recent 8.2% one day share price gain sits against a weaker backdrop, with a year to date share price return of 37.24% decline and a 1 year total shareholder return of 62.27% decline. This suggests short term momentum has picked up while longer term performance...
NYSE:HCA
NYSE:HCAHealthcare

HCA Expands Florida Footprint And Refines Messaging With New Leadership

HCA Healthcare (NYSE:HCA) is opening a new full-service hospital in Gainesville, the first new facility of its kind in the area in more than 50 years. The company is planning a substantial expansion at Kendall Hospital in Miami-Dade, aimed at increasing capacity and service reach in South Florida. Cynthia Cifuentes-Finkel has been appointed senior vice president of marketing and corporate affairs, with responsibility for brand leadership and stakeholder engagement. For investors watching...
NasdaqGS:ALGN
NasdaqGS:ALGNMedical Equipment

Align Technology (ALGN) Is Down 5.6% After Earnings Beat And New Buyback - Has The Bull Case Changed?

In late April 2026, Align Technology reported first-quarter sales of US$1,040.09 million and net income of US$112.77 million, beating analyst expectations while reaffirming its full-year 2026 guidance and announcing an additional US$200 million share repurchase under its existing US$1 billion program. At the same time, Align used the AAO 2026 conference to showcase advances across its digital orthodontic platform, including 3D printed attachment systems, enhanced palatal expanders, and...
NYSE:ATEN
NYSE:ATENSoftware

Is It Too Late To Consider A10 Networks (ATEN) After Its Strong Multi‑Year Rally?

If you are wondering whether A10 Networks at around US$26.85 is priced attractively or already baking in a lot of optimism, this breakdown is designed to help you frame that question clearly. The stock has seen a 2.6% decline over the last 7 days, alongside returns of 11.9% over 30 days, 54.8% year to date, 65.9% over 1 year, 104.3% over 3 years and 214.4% over 5 years. These movements can change how the market views both its potential and its risks. Recent coverage has focused on A10...
NasdaqGS:CHYM
NasdaqGS:CHYMDiversified Financial

Chime Financial Taps Classroom AI Partnership To Shape Long Term Brand Story

Chime Financial (NasdaqGS:CHYM) has partnered with Junior Achievement USA to roll out AI powered financial literacy programs for students. The partnership includes a redesign of the JA Finance Park program to introduce interactive, experiential money management and career readiness modules. The initiative launches during Financial Literacy Month and focuses on preparing young people for real world financial decisions. For investors tracking Chime Financial, the partnership arrives as the...
NasdaqGM:RZLV
NasdaqGM:RZLVSoftware

Rezolve AI Revolut Listing Expands SQD Reach While Valuation Questions Linger

Rezolve AI's SQD token has been listed on Revolut, expanding access to more than 70 million users worldwide. The listing brings SQD onto a large mainstream fintech platform, beyond crypto focused exchanges. This move is positioned as a step toward mass market adoption of Rezolve AI's decentralized AI commerce infrastructure. Rezolve AI, listed as NasdaqGM:RZLV, is building a decentralized AI commerce infrastructure designed to connect agentic AI systems with real world transactional data...
NasdaqGS:ERAS
NasdaqGS:ERASBiotechs

Erasca Confronts Trial Fatality And Lawsuit As Valuation Debate Deepens

Erasca (NasdaqGS:ERAS) disclosed a patient death in its Phase 1 ERAS-0015 trial, triggering heightened safety and regulatory scrutiny. Revolution Medicines filed a patent infringement lawsuit against Erasca, also challenging the way ERAS-0015 has been compared to its own programs. These events follow a recent preliminary positive data update for ERAS-0015 and introduce fresh uncertainty around the asset and broader pipeline. Erasca comes into this twin shock with a share price of $10.03 and...
NasdaqGS:MDGL
NasdaqGS:MDGLBiotechs

Is It Time To Reassess Madrigal Pharmaceuticals (MDGL) After Its Strong Five Year Share Price Gain

If you are trying to figure out whether Madrigal Pharmaceuticals is priced attractively today, the starting point is understanding what the current share price really reflects. The stock most recently closed at US$513.72, with returns of 0.3% over 7 days, a 6.1% decline over 30 days, a 13.5% decline year to date, a 62.8% return over 1 year, a 67.7% return over 3 years, and a very large 5 year gain of 293.9%. These mixed short term and longer term moves have kept Madrigal on the radar of...
NYSE:SEI
NYSE:SEIEnergy Services

A Look At Solaris Energy Infrastructure (SEI) Valuation After Strong Q1 Results And Expanded Long Term Power Contracts

Solaris Energy Infrastructure (SEI) is back in focus after first quarter 2026 results showed higher sales, revenue, and net income versus a year earlier, along with raised earnings guidance and expanded long term power contracts. See our latest analysis for Solaris Energy Infrastructure. SEI shares have cooled slightly after recent highs, with a 1 day share price return of 2.04% and a relatively flat 7 day move. However, the 30 day share price return of 29.62% and year to date gain of 43.91%...
NasdaqGS:ANAB
NasdaqGS:ANABBiotechs

Assessing AnaptysBio’s Valuation After Strong Recent Share Price Momentum

Why AnaptysBio is on investors’ radar AnaptysBio (ANAB) has attracted attention after a recent share price move, with the stock showing double digit returns over the past week, month and past 3 months. This performance is prompting some investors to reassess its profile. See our latest analysis for AnaptysBio. Beyond the recent surge, the momentum in AnaptysBio’s share price return has been building for some time, and the very large 1 year total shareholder return suggests investors have been...
NYSE:CLVT
NYSE:CLVTProfessional Services

Is Clarivate (CLVT) Now A Potential Opportunity After Recent 35% One Year Share Price Jump?

Wondering whether Clarivate at US$2.79 is a bargain or a value trap? This article breaks down what that price really implies about the business. The stock has moved 13.9% over the last 7 days and 10.3% over the last 30 days, while the year to date return is 13.9% and the 1 year return is 35.4%. Recent coverage has focused on Clarivate's role within professional services and the information solutions space, with attention on how its products fit into clients' long term workflows and budgets...
NasdaqGS:TFSL
NasdaqGS:TFSLBanks

Did Record Net Interest Income and Stable EPS Just Shift TFS Financial's (TFSL) Investment Narrative?

TFS Financial Corporation has reported past second-quarter 2026 results, with net interest income rising to US$77.81 million and net income to US$23.25 million, while earnings per share reached US$0.08, up from US$0.07 a year earlier. Behind these steady figures, the bank’s higher yields from resetting Smart Rate ARMs and tight deposit cost control underpinned record net interest income and a strong Tier 1 capital position. We’ll now look at how this earnings stability, underpinned by...
NYSE:CPA
NYSE:CPAAirlines

Is Copa Holdings (CPA) Still Attractive After A 29.9% One Year Share Price Gain?

Wondering if Copa Holdings at around US$116 is priced for opportunity or already reflects the story investors care about? This article focuses squarely on what the current share price might be implying about value. The stock is down 4.6% year to date, but up 29.9% over the last year, which naturally raises questions about how much of that performance is already built into expectations. Recent news coverage has focused on Copa Holdings within broader airline and travel sector discussions,...
NYSE:LAZ
NYSE:LAZCapital Markets

Lazard (LAZ) Margin Compression Challenges Bullish Earnings Recovery Narratives

Lazard (LAZ) has just posted its Q1 2026 update, with the most recent full quarter of detail showing Q4 2025 revenue of US$892.6 million and basic EPS of US$0.49, alongside trailing twelve month revenue of about US$3.1 billion and EPS of US$2.37. Over the past few reported quarters, revenue has moved from US$811.4 million in Q4 2024 to US$892.6 million in Q4 2025, while basic EPS shifted from US$0.89 to US$0.49. This sets up a results season where revenue scale and pressure on per share...